eligibility_summary
Adults (≥18) with grade 1–3A FL (transformed allowed), relapsed/refractory after ≥2 lines, ECOG 0–2, CAR‑T eligible (CrCl ≥45, Hgb ≥8, ALT/AST ≤2.5×ULN or ≤5× with liver involvement, SpO2 ≥92%), ≥1 measurable lesion, prior RT allowed, FOCBP negative pregnancy test, consent. Exclude: other active cancer therapy <3y, pregnancy/breastfeeding, urgent bridging chemo/rituximab, RT beyond OAR limits, aminoglycoside allergy, uncontrolled IV-treated infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm study in relapsed/refractory follicular lymphoma testing: 1) Axicabtagene ciloleucel (axi-cel): autologous, gene-modified cellular immunotherapy (anti-CD19 CAR T cells with CD28 costimulation). Mechanism: CAR engagement of CD19 on B cells activates T-cell signaling (CD3ζ/CD28), leading to cytotoxic killing and cytokine release. 2) Bridging radiotherapy (external-beam): induces DNA damage for tumor cytoreduction and may enhance immune priming. 3) Lymphodepletion: cyclophosphamide (alkylating agent) + fludarabine (purine analog) to deplete host lymphocytes and support CAR T expansion. Supportive meds: prednisone (glucocorticoid immunosuppressant for toxicity), diphenhydramine (H1 blocker), acetaminophen (antipyretic). Targets/pathways: CD19+ malignant B cells, CAR T activation pathways, host lymphocyte depletion, and RT-induced tumor cell death/immune modulation.